We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Real-Time PCR Detects Drug Resistant Tubercle Bacillus

By LabMedica International staff writers
Posted on 03 Aug 2010
A new diagnostic test identifies drug resistance genes of Mycobacterium tuberculosis (TB) in various human biological materials

The real-time polymerase chain reaction (RT-PCR) test can simultaneously detect TB and the mutations of drug resistant TB genes in sputum, aseptic and pleural fluid, blood, bone marrow aspiration, bronchial washing, fresh tissue, culture specimens (solid and liquid culture), urine and stool. More...
The test for multi-drug resistant TB (MDR-TB) is completed within four hours.

Healthcare workers will be able to determine quickly whether or not a patient is infected with a strain of TB that is resistant to first line drugs such as isoniazid (INH) and rifampin (Rif). The Anyplex MDR-TB is a real-time detection test of M. tuberculosis that quickly and comprehensively determines the levels of targets in a patient's various sample types, and identifies mutations of drug resistant genes, which will aid physicians to make the correct diagnostic choices.

The Anyplex MDR-TB test is manufactured by Seegene (Rockville, MD, USA). The test can detect the mutations of drug resistant genes to Rif (rpoB: D516V/Y, H526D/Y, S531L) and INH (katG: S315T (2 cases); inhA promoter: -15(C/T)). The unprecedented speed and accuracy of the Anyplex MDR-TB Tests will enable doctors and clinicians to provide quickly an appropriate treatment to prevent the spread of MDR-TB.

Current TB test methods based on culture and microscopy are hindered by speed, low sensitivity, and low specificity. Furthermore, none of these approaches are able to identify rapidly and efficiently a patient's resistance to the major drugs for treating TB. Even if sequencing and Line Probe Assay are available to test drug resistance, the procedures are quite complicated and time-consuming.

The World Health Organization (WHO; Geneva, Switzerland), reported that TB strains that are resistant to all major anti-TB drugs have been documented in every country by the nongovernmental organization recent survey. A particularly dangerous form of drug-resistant TB is MDR-TB, caused by TB bacilli resistant to the most powerful anti-TB drugs. The rate for successful MDR-TB treatment is extremely low and the progress of the disease is faster than normal TB, resulting in 40% - 50% of mortality rate.

Jong-Yoon Chun, CEO of Seegene, said, "Because MDR-TB is difficult to treat, preventing its spread throughout the population is essential. The Anyplex MDR-TB Test is a powerful new tool that healthcare workers can use to rapidly determine such infections, which will both help stop it from spreading and allow health care professionals to set a course of alternative medications for infected patients."

Related Links:
Seegene
WHO


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.